0
On Monday, Protagonist Therapeutics, Inc. (NASDAQ:PTGX) announced topline results from ANTHEM-UC Phase 2b study of icotrokinra (JNJ-2113) in adults with moderately to severely active ulcerative colitis (UC).
The study conducted by Protagonist’s collaboration partner, Johnson & Johnson, met its primary endpoint of clinical response in all icotrokinra dose groups evaluated.
Additionally, the study demonstrated clinically meaningful differences versus placebo in key secondary endpoints of clinical remission, symptomatic remission and endoscopic improvement at Week 12.
- All three doses of once daily icotrokinra met the primary endpoint of clinical response at Week 12.
- At Week 12, patients treated with the highest dose of icotrokinra achieved a response rate of 63.5% versus 27.0% for placebo.
- 30.2% of patients treated with the highest dose of icotrokinra demonstrated clinical remission at Week 12, compared to 11.1% of patients who received placebo.
- Clinical remission and response rates continued …
